Pfizer to close Hospira deal in September; U.K. cell manufacturing facility moves forward;

> Pfizer ($PFE) says it has all of the antitrust approvals it needs and will close on its $15 billion buyout of Hospira ($HSP) in early September. Release

> Merck KGaA stopped production July 31 at a facility in India where it made teaching kits, tech ware and molecular biology reagents and is in the process of shutting it down. Report

> Shire ($SHPG) has a new agreement with Sanquin Blood Supply, which has been the exclusive manufacturer of Cinryze, the rare disease drug it got in its $4.2 billion buyout of ViroPharma, which will allow it to use other contractors to increase production of the drug. Release

> Plans for a £55 million large-scale manufacturing facility to be run by England's Cell Therapy Catapult has been approved by local authorities in Hertfordshire. Report

> Chicago-based contract manufacturer Regis Technologies has completed a 36,000-square-foot potent compound suite to manufacturer potent APIs. Release

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.